🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 53 of 116

  1. Iparomlimab and Tuvonralimab Injection in combination with TFOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  3. Iparomlimab/Tuvonralimab

    Chinese University of Hong Kong

    LOCALLY ADVANCED CERVICAL CANCERS

    phase 2 small molecule active

    1 trial

  4. Iparomlimab/Tuvonralimab

    The First People's Hospital of Lianyungang

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  5. Ipilimumab

    United Therapeutics Europe Ltd

    Locally Advanced Clear Cell Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  6. Ipilimumab

    United Therapeutics Europe Ltd

    BCLC Stage B Hepatocellular Carcinoma

    phase 2 mab terminated

    1 trial

  7. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  8. Irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL , IRINOTECAN , Fluorouracil Hikma 50 mg/ml Injektionslösung, Ribofolin® 10 mg/ml Injektionslösung, JNJ-61186372, OXALIPLATIN , CALCIUM FOLINATE , JNJ-61186372, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    Janssen-Cilag International N.V.

    Advanced or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, PALBOCICLIB, Palbociclib, TEMOZOLOMIDE, TEMOZOLOMIDE, PALBOCICLIB, PALBOCICLIB, TEMOZOLOMIDE, Temozolomide SUN 5 mg hard capsules, Endoxan®, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    Pfizer Australia Pty Ltd

    recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma

    phase 2 small molecule active

    1 trial

  11. Irinotecan Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  12. Irofulven

    Allarity Therapeutics

    Metastatic Castration-Resistant Prostate Cancer Patients

    phase 2 small molecule completed

    1 trial

  13. Irosustat

    United Therapeutics Europe Ltd

    Breast Neoplasms

    phase 2 small molecule terminated

    1 trial

  14. Isatuximab, Dexamethason 8 mg JENAPHARM®, Dexamethason 4 mg JENAPHARM®, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  15. Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  16. Ivaltinostat

    CG Oncology

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. Ivonescimab

    Summit Therapeutics

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  18. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  19. Ivonescimab

    Summit Therapeutics

    Metastatic Esophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. Ivonescimab

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    3 trials

  21. Ivonescimab

    Summit Therapeutics

    Stomach Cancer Stage IV

    phase 2 small molecule active

    1 trial

  22. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  23. Ivonescimab

    Summit Therapeutics

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  24. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  25. Ivonescimab

    Summit Therapeutics

    Endometrial Cancer

    phase 2 small molecule active

    1 trial

  26. Ivonescimab

    Summit Therapeutics

    Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  27. Ivonescimab

    Summit Therapeutics

    Thymus Carcinoma

    phase 2 mab active

    1 trial

  28. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  29. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 small molecule active

    1 trial

  30. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  31. Ivonescimab combined with TP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  32. Ivosidenib combined with venetoclax and azacitidine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  33. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  34. Ixazomib

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  35. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 small molecule terminated

    1 trial

  36. Ixazomib

    Takeda

    Mantle Cell Lymphoma

    phase 2 small molecule active

    2 trials

  37. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  38. JCAR017

    Celgene Europe Limited

    Lymphoma, Non-Hodgkin

    phase 2 small molecule completed

    1 trial

  39. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  40. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  41. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  42. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  43. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  44. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  45. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  46. JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  47. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  48. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.